Novo Nordisk's Trial Drug Outperforms Zepbound in Weight Loss
Novo Nordisk reports that its experimental next-generation obesity drug, positioned as a successor to Wegovy, produced greater weight loss than Eli Lilly's Zepbound in a head-to-head clinical trial. The result intensifies competition in the GLP-1 weight-loss drug market between the two dominant manufacturers. No regulatory approval or launch timeline was announced, and pricing or Medicaid coverage decisions are not yet at issue. For Medicaid stakeholders, the news signals that pipeline competition in this drug class will continue to grow, with implications for future coverage and cost pressure once new products reach market.
State Medicaid programs already grappling with high GLP-1 drug spending should anticipate even more competitive, high-cost entrants in this class, sharpening future formulary and utilization management decisions.
Pharmacy
You might also like